Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.64 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | XBP1 | P17861 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203697 | 0.84 | HPGD (0.59) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL26088749 | 0.78 | HPGD (0.56) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL26088689 | 0.76 | MAPK1 (0.61) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL69310 | 0.75 | HPGD (1.00) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL22137286 | 0.75 | ALDH1A1 (0.55) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL10618518 | 0.75 | MAPK1 (0.75) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL11646686 | 0.74 | CYP1A2 (0.66) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL7480180 | 0.74 | HPGD (0.51) | HPGDMAPK1TSHRALDH1A1CYP1A2 | |
| SCHEMBL22137275 | 0.74 | ALDH1A1 (0.54) | HPGDMAPK1TSHRALDH1A1LMNA | |
| SCHEMBL8204552 | 0.73 | BRD4 (0.62) | HPGDMAPK1TSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452168-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2016-09-27 | — | — | US | disclosed |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-08-27 | — | — | US | disclosed |
| US-8993574-B2 | Pyrrole antifungal agents | F2G LTD (GB) | 2015-03-31 | — | — | US | disclosed |
| EP-2283006-B1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2015-02-25 | — | — | EP | disclosed |
| EP-2626361-B1 | Pyrrole antifungal agents | F2G LTD (GB) | 2014-10-15 | — | — | EP | disclosed |
| EP-2626361-A1 | Pyrrole antifungal agents | F2G Limited (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2011-06-23 | — | — | US | disclosed |
| EP-2283006-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G Limited (GB) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009130481-A1 | PYRROLE ANTIFUNGAL AGENTS | F2G LTD (GB) | 2009-10-29 | — | — | WO | disclosed |
| EP-0591355-B1 | PORPHYCENE COMPOUNDS FOR PHOTODYNAMIC THERAPY | CYTOPHARM INC (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5409900-A | Treatment of cancer tumors, psoriasis; purification of blood | CYTOPHARM, INC. (US) | 1995-04-25 | — | — | US | disclosed |
| EP-0591355-A4 | PORPHYCENE COMPOUNDS FOR PHOTODYNAMIC THERAPY. | CYTOPHARM INC (US) | 1995-01-18 | — | — | EP | disclosed |
| EP-0591355-A1 | PORPHYCENE COMPOUNDS FOR PHOTODYNAMIC THERAPY | CYTOPHARM, INC. (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5262401-A | Porphyrins as antitumor agents and psoriasis treatment | CYTOPHARM, INC. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5179120-A | Antitumor agents or psoriasis | CYTOPHARM, INC. (US) | 1993-01-12 | — | — | US | disclosed |
| WO-1993000087-A1 | PORPHYCENE COMPOUNDS FOR PHOTODYNAMIC THERAPY | CYTOPHARM, INC. (US) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152285-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | HPGD 2971/4885MAPK1 1181/4885TSHR 1769/4885 |
| US-20150238500-A1 | PYRROLE ANTIFUNGAL AGENTS | FOXM1, PYCR1, ARG1 | HPGD 2971/4885MAPK1 1181/4885TSHR 1769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.